Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus AMTURNIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus AMTURNIDE.
ALDORIL 15 vs AMTURNIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
10 mg to 20 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination